centerforbiosimilars13h
Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential
Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...
centerforbiosimilars1d
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA ...
centerforbiosimilars4d
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...
centerforbiosimilars5d
Interchangeable Aflibercept Biosimilar, Enzeevu, Comparable With Eylea for nAMD
Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in patients with neovascular age-related macular degeneration (nAMD). Enzeevu ...
centerforbiosimilars5d
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...
centerforbiosimilars6d
Christina Corridon, MPH, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars6d
Scott Shields, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars6d
Luke Halpern
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars6d
Peter Page
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars6d
Wayne Winegarden, PhD
The Top 5 Biosimilar Articles for the Week of December 2 ...